Relationship Between Medical Therapy, Long-Term Care Insurance, and Comorbidity in Elderly Patients With Heart Failure With Systolic Dysfunction

Abstract

to that in patients with HFrEF. 7 Nonetheless, most patients have been treated inadequately and have had no changes in the use or dose of the medication suggested; thus, there remain significant gaps in the guidelines' recommendations. 8,9 In implementing guideline-directed medical therapy (GDMT), patient-related factors (comorbidities, advanced age, frailty, cognitive impairment, poor adherence, low socioeconomic status), treatment-related factors (intolerance, side effects), and healthcare-related factors C urrent management guidelines for patients with heart failure with reduced ejection fraction (HFrEF) strongly support the use of multiple medications that are proven to improve survival and quality of life. 1,2 Moreover, evidence that the standard therapy for HFrEF may be effective in and extended to select patients with heart failure with mildly reduced ejection fraction (HFmrEF) has grown. 3-6 In daily clinical practice in Japan, the medication regimen in patients with HFmrEF is similar

Patients with acute decompensated heart failure in an area with a super-aging society; A single- center, retrospective cohort study

“…Although the JCS guidelines recommend ACEI/ARB, BB, and MRA to improve the prognosis of HFrEF, the induction rates of ACEI/ARB, BB, and MRA tended to be low for HFrEF in this study (62.9%, 73.4%, and 29.8%, respectively). This was not su cient compared with previous clinical studies, and age and renal function could have affected the results [10][11][12]. In patients with HFrEF, the incidence of composite events did not differ between those treated with and without ACEI/ARB, BB, or MRA.…”